Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE
    • Publication Information:
      Publication: <2011-> : [New York] : Elsevier
      Original Publication: Dallas, Tex. : Cancer Information Group, c2001-
    • Subject Terms:
      Cancer Care Facilities/*statistics & numerical data ; Dermatologic Agents/*therapeutic use ; Drug Eruptions/*drug therapy ; Medication Adherence/*statistics & numerical data ; Protein Kinase Inhibitors/*adverse effects; Adult ; Aged ; Aged, 80 and over ; Colorectal Neoplasms/drug therapy ; Drug Eruptions/diagnosis ; Drug Eruptions/epidemiology ; Drug Eruptions/etiology ; Drug Prescriptions/statistics & numerical data ; ErbB Receptors/antagonists & inhibitors ; Female ; France/epidemiology ; Germany/epidemiology ; Humans ; Incidence ; Male ; Middle Aged ; Nurses/statistics & numerical data ; Oncologists/statistics & numerical data ; Quality of Life ; Severity of Illness Index ; Spain/epidemiology ; Surveys and Questionnaires/statistics & numerical data
    • Abstract:
      Introduction: This study aimed to provide a description of existing measures for the prevention and management of epidermal growth factor receptor inhibitor monoclonal antibody-induced skin toxicities and factors impacting patients' adherence to those measures in France, Germany, and Spain.
      Materials and Methods: The study consisted of 2 separate surveys. Health care professionals (HCPs; oncologists and nurses) in France, Germany, and Spain were interviewed, and patients with metastatic colorectal cancer and head-and-neck cancer in France and Germany self-completed questionnaires. The study was conducted between February and July 2018.
      Results: A total of 53 oncologists, 44 nurses, and 143 patients participated in the study. HCPs stated that skin toxicities moderately (52%) or severely (28%) impacted patient care. Ninety percent of HCPs reported routine provision of prophylactic measures. The great majority of patients self-reported adherence with the prophylactic (80% to 88% depending on the type of measures) and reactive (93% to drug prescription) skin toxicity recommendations. HCPs estimated patient adherence to be 45% for full adherence and 40% for partial adherence. Most HCPs reported a positive or very positive impact of preventive measures and recommendations on skin toxicity incidence and severity, patients' quality of life, and various aspects of quality of anti-cancer treatment.
      Conclusions: Skin toxicities are an important adversity negatively impacting on patient care. However, despite the positive perception of the effectiveness of skin toxicity prophylaxis, almost one-third of oncology centers did not provide formal guidelines, and 10% of HCPs did not provide routine prophylactic measures. Patient adherence appears to be high for epidermal growth factor receptor inhibitor monoclonal antibody-induced skin toxicity prevention measures.
      (Copyright © 2020 Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Epidermal growth factor receptor inhibitor; Prophylaxis; Quality of life; Rash; Treatment discontinuation
    • Accession Number:
      0 (Dermatologic Agents)
      0 (Protein Kinase Inhibitors)
      EC 2.7.10.1 (EGFR protein, human)
      EC 2.7.10.1 (ErbB Receptors)
    • Publication Date:
      Date Created: 20200302 Date Completed: 20210510 Latest Revision: 20210510
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.clcc.2020.01.001
    • Accession Number:
      32113902